COMPANIES›BRIO PHARMACEUTICALS INC
✓ Verified H1B Sponsor

BRIO PHARMACEUTICALS INC

Houston, TXEIN 923035367
TRUST SCORE
92.4
High Trust
12
FY2024 H1B Approvals
12
All-time Approvals
92.4
Trust Score / 100

TOP SPONSORED JOB CATEGORIES

ChemistsValidation EngineersHealth Informatics Specialists

RECENT H1B FILINGS

JOB TITLELOCATIONWAGEDATE
ChemistsHouston, TX$35.9Oct 2025
Validation EngineersHouston, TX$33.66Oct 2025
ChemistsHouston, TX$63,357Oct 2025
Supply Chain ManagersHouston, TX$33.05Sep 2025
ChemistsHouston, TX$35.9Aug 2025
ChemistsHouston, TX$35.9Aug 2025
Validation EngineersHouston, TX$33.66Jun 2025
Validation EngineersHouston, TX$33.66Nov 2024
ChemistsHouston, TX$41.88Oct 2024
ChemistsHouston, TX$41.88Oct 2024
ChemistsHouston, TX$41.88Oct 2024
Validation EngineersHouston, TX$71,677Oct 2024
Health Informatics SpecialistsHouston, TX$65,894Oct 2024
Validation EngineersHouston, TX$71,677Oct 2024
Health Informatics SpecialistsHouston, TX$65,894Oct 2024

SHOWING 50 MOST RECENT · SOURCE: DOL LCA PUBLIC DATA FY2024 · EIN 923035367

FREQUENTLY ASKED QUESTIONS

Does BRIO PHARMACEUTICALS INC sponsor H1B visas?

Yes. BRIO PHARMACEUTICALS INC has an active H1B sponsorship history with 12 total approved LCA filings on record, including 12 approvals in FY2024. Data sourced from US Department of Labor public disclosure files.

How many H1B visas has BRIO PHARMACEUTICALS INC sponsored?

According to DOL LCA data, BRIO PHARMACEUTICALS INC has 12 all-time H1B approvals and 12 approvals in fiscal year 2024.

What types of roles does BRIO PHARMACEUTICALS INC sponsor H1B for?

BRIO PHARMACEUTICALS INC most commonly sponsors H1B visas for: Chemists, Validation Engineers, Health Informatics Specialists. This is based on their DOL Labor Condition Application filing history.

Is BRIO PHARMACEUTICALS INC a reliable H1B sponsor?

BRIO PHARMACEUTICALS INC has a Trust Score of 92.4/100 on KEEL, calculated from total approval volume, recency of filings, and approval consistency based on DOL LCA data.

DATA SOURCE: US DEPT. OF LABOR · LCA PUBLIC DISCLOSURE FY2023–FY2024